<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.1012485</article-id><article-id pub-id-type="publisher-id">ACM-39510</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20201200000_75607282.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  早期胃癌行内镜下治疗术后根除幽门螺旋杆菌的研究进展
  Research Progress on Eradication of Helicobacter pylori after Endoscopic Treatment for Early Gastric Cancer
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>子玥</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>马</surname><given-names>东瑞</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>贵生</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>陕西省人民医院，陕西 西安</addr-line></aff><aff id="aff2"><addr-line>延安大学，陕西 延安</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>07</day><month>12</month><year>2020</year></pub-date><volume>10</volume><issue>12</issue><fpage>3240</fpage><lpage>3245</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    早期胃癌的诊断与治疗随着内镜技术的发展得到了提高，但早期胃癌内镜下治疗术后同步胃癌、异时性胃癌的发生引起了广泛得关注，根除幽门螺旋杆菌是否影响异时性胃癌的发生及发展值得我们关注。&lt;br/&gt;The diagnosis and treatment of early gastric cancer have been improved with the development of endoscopic technology, but the occurrence of synchronous gastric cancer and heterochronous gastric cancer after endoscopic treatment of early gastric cancer has aroused widespread concern. Whether eradication of Helicobacter pylori affects the occurrence and development of heterochronous gastric cancer deserves our attention. 
  
 
</p></abstract><kwd-group><kwd>早期胃癌，幽门螺旋杆菌，异时性胃癌，同步胃癌, Early Gastric Cancer</kwd><kwd> Helicobacter pylori</kwd><kwd> Heterochronous Gastric Cancer</kwd><kwd> Synchronous Gastric Cancer</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>早期胃癌的诊断与治疗随着内镜技术的发展得到了提高，但早期胃癌内镜下治疗术后同步胃癌、异时性胃癌的发生引起了广泛得关注，根除幽门螺旋杆菌是否影响异时性胃癌的发生及发展值得我们关注。</p></sec><sec id="s2"><title>关键词</title><p>早期胃癌，幽门螺旋杆菌，异时性胃癌，同步胃癌</p></sec><sec id="s3"><title>Research Progress on Eradication of Helicobacter pylori after Endoscopic Treatment for Early Gastric Cancer</title><p>Ziyue Liu<sup>1</sup>, Dongrui Ma<sup>2</sup>, Guisheng Liu<sup>2</sup></p><p><sup>1</sup>Yan’an University, Yan’an Shaanxi</p><p><sup>2</sup>Shaanxi Provincial People’s Hospital, Xi’an Shaanxi</p><p><img src="//html.hanspub.org/file/55-1571764x4_hanspub.png" /></p><p>Received: Nov. 27<sup>th</sup>, 2020; accepted: Dec. 23<sup>rd</sup>, 2020; published: Dec. 30<sup>th</sup>, 2020</p><p><img src="//html.hanspub.org/file/55-1571764x5_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>The diagnosis and treatment of early gastric cancer have been improved with the development of endoscopic technology, but the occurrence of synchronous gastric cancer and heterochronous gastric cancer after endoscopic treatment of early gastric cancer has aroused widespread concern. Whether eradication of Helicobacter pylori affects the occurrence and development of heterochronous gastric cancer deserves our attention.</p><p>Keywords:Early Gastric Cancer, Helicobacter pylori, Heterochronous Gastric Cancer, Synchronous Gastric Cancer</p><disp-formula id="hanspub.39510-formula15"><graphic xlink:href="//html.hanspub.org/file/55-1571764x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/55-1571764x7_hanspub.png" /> <img src="//html.hanspub.org/file/55-1571764x8_hanspub.png" /></p></sec><sec id="s5"><title>1. 前言</title><p>胃癌是全球五大常见的癌症，也是引起癌症死亡的第三大原因 [<xref ref-type="bibr" rid="hanspub.39510-ref1">1</xref>]。随着内镜等相关技术的发展，胃癌通过内镜下活检后在组织学上得到诊断，同时结合CT，内镜超声，PET和腹腔镜进行分期。早期胃癌给予内镜下或外科手术治疗。治疗术后胃的保留，可发生复发性、异时性胃癌。晚期胃癌(局部晚期或转移性)患者预后较差，姑息性化疗是治疗的主要手段 [<xref ref-type="bibr" rid="hanspub.39510-ref2">2</xref>]。幽门螺旋杆菌引起胃部炎症，同时是引起胃癌最大的危险因素。通过这篇文章，我们将对胃癌在全球的发病情况、幽门螺旋杆菌感染、关于早期胃癌内镜下治疗，以及根除幽门螺旋杆菌在早期胃癌行内镜下治疗后的影响及作用、是否降低异时性胃癌的发病率做进一步的阐述。</p></sec><sec id="s6"><title>2. 胃癌发病情况及幽门螺旋杆菌</title><p>2007至2017年间，胃癌从癌症(粗) YLLs的第二大病因上升到第三位，绝对YLLs增加了5% (95% UI, 2%~7%)，且发病率增加了25% (95% UI, 22%~29%)，至2017年全球共有120万胃癌患者 [<xref ref-type="bibr" rid="hanspub.39510-ref3">3</xref>]。国际癌症研究机构(International Agency for Research on Cancer, IARC)指出2018年全球胃癌新发病例约103万，东亚胃癌发病率排名第一，大约是东欧地区发病率的2倍，胃癌是全球排名第五位恶性肿瘤 [<xref ref-type="bibr" rid="hanspub.39510-ref4">4</xref>]。杨等人 [<xref ref-type="bibr" rid="hanspub.39510-ref5">5</xref>] 通过分析2000~2014年间我国22个肿瘤登记处的胃癌发病与时间的关系，得出我国胃癌发病率整体趋于平稳且标化率显著降低，但发病数明显上升，而人口老龄化是我国胃癌发病数显著增加的主要原因，并预计2020年我国胃癌发病率为24.30/10万，新发病例中60岁以上的人群将占到71.8%。关于幽门螺旋杆菌，国际癌症研究机构(IARC)认为其是I类胃癌相关致癌物 [<xref ref-type="bibr" rid="hanspub.39510-ref6">6</xref>]。同时国际杂志上发表的一篇文章称HP感染产生的促炎症因子促进了炎症相关肿瘤的发生，慢性胃粘膜炎症伴幽门螺杆菌感染是多中心/多灶性肿瘤发生的基础 [<xref ref-type="bibr" rid="hanspub.39510-ref7">7</xref>]。所以在幽门螺旋杆菌感染的患者中，胃癌可经常发生在多个部位。而根除幽门螺杆菌被认为对胃癌的生长和新的胃癌的发生都有抑制作用 [<xref ref-type="bibr" rid="hanspub.39510-ref8">8</xref>]。关于全球幽门螺旋杆菌流行情况，Hooi等人通过系统评价和Meta分析，至2015年全球约有44亿人——超过世界人口的一半——感染了幽门螺杆菌，各地区之间存在很大差异。亚洲2000年之前的幽门螺旋杆菌感染率为53.6%，2000年后幽门螺旋杆菌感染率为54.3% [<xref ref-type="bibr" rid="hanspub.39510-ref9">9</xref>]。幽门螺旋杆菌感染是全球严重医疗问题，所以幽门螺旋杆菌感染的胃癌患者值得我们关注。</p></sec><sec id="s7"><title>3. 早期胃癌内镜下诊断</title><p>早期胃癌的内镜下诊断应分步进行，报告结果应以巴黎分类作为标准。同时在内镜诊断的过程中应注意以下三个方面，一是内镜检查前应进行充分准备，减少胃内粘液避免影响内镜下视野，比如术前消泡剂的应用；第二，标准化胃地图绘制程序的使用，避免内镜检查中的盲点。虽然病变的检测容易程度随着检查的时间与拍摄照片数量的增多而增加，但因为临床的需要，欧洲胃肠内窥镜学会 [<xref ref-type="bibr" rid="hanspub.39510-ref10">10</xref>] 建议拍摄8张图像对胃的整体检查做出相关说明；第三，对胃黏膜细微检查的相关内窥镜技术的应用，可分辨光谱成像彩色增强(FICE)内镜加或不加放大率(FIME)和共聚焦激光内窥镜(CLE)已经被用于EGC的诊断，但目前具有或不带有放大的窄带成像(NBI-ME)的新型高分辨率(HR)虚拟染色内窥镜技术应用更加有助于早期胃癌的诊断。早期胃癌在内镜下的变化并不明显，增加了诊断困难，作为一名内镜医师，需要良好的培训，以及对相关专业方面新技术的熟悉是必要的。</p></sec><sec id="s8"><title>4. 早期胃癌的治疗及相关指南</title><p>根据第3版日本胃癌分类，早期胃癌是由T1肿瘤组成，与淋巴结转移无关。T1肿瘤指局限于粘膜(M)或粘膜下层(SM)，而T1肿瘤可进一步分为T1a肿瘤局限于粘膜(M)、T1b肿瘤局限于粘膜下层(SM)。窄带成像放大内镜(ME-NBI)可以评估早期胃癌的侧向扩散和组织学类型以及行针对性的活检是，同时ME-NBI的使用正在稳定增加 [<xref ref-type="bibr" rid="hanspub.39510-ref11">11</xref>] [<xref ref-type="bibr" rid="hanspub.39510-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.39510-ref13">13</xref>]。所以ME-NBI的使用有助于早期胃癌的诊断。对于早期胃癌给予内镜下内镜黏膜切除术(EMR)或内镜黏膜下剥离术(ESD)治疗，是目前公认的治疗方法。2014年日本胃癌治疗指南 [<xref ref-type="bibr" rid="hanspub.39510-ref14">14</xref>] 指出胃癌内镜切除的适应症见表1所示。但日本胃癌协会在2018年 [<xref ref-type="bibr" rid="hanspub.39510-ref15">15</xref>] 则将通过内窥镜切除的胃癌病变分为绝对适应征、扩大适应症、相对适应症，文字总结见表2，同时在绝对适应症里突出强调了内镜下治疗方式得选择。关于早期胃癌行内镜下ESD或EMR治疗，ESD要优于EMR。一项关于早期胃癌内镜下粘膜清扫术与EMR的荟萃癌内镜黏分析显示与内镜下粘膜切除术相比，ESD获得了更高的组织学完全切除率和更低的局部复发率 [<xref ref-type="bibr" rid="hanspub.39510-ref16">16</xref>]。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Indications for endoscopic resection in the 2014 Japanese guidelines for the treatment of gastric cance</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >内镜切除胃癌适应症</th><th align="center" valign="middle" ></th></tr></thead><tr><td align="center" valign="middle" >绝对适应症</td><td align="center" valign="middle" >未见溃疡的分化型腺癌[UL(−)]，临床诊断浸润深度为T1a，直径 ≤ 2 cm</td></tr><tr><td align="center" valign="middle" >扩大适应症</td><td align="center" valign="middle" >不伴有淋巴血管浸润[ly(−), v(−)]，临床诊断为T1a的以下类型的肿瘤</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >a) 分化型，UL(−)，但直径 &gt; 2 cm。 b) 分化型，UL(+)，直径 ≤ 3 cm。 c) 未分化型，UL(−)，直径 ≤ 2厘米。</td></tr></tbody></table></table-wrap><p>表1. 2014年日本胃癌治疗指南内镜切除适应症</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Indications for endoscopic resection in the 2018 Japanese guidelines for the treatment of gastric cance</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >内镜切除胃癌病变适应症</th><th align="center" valign="middle" ></th></tr></thead><tr><td align="center" valign="middle" >绝对适应症</td><td align="center" valign="middle" >1. ESD或EMR绝对适应症： 无溃疡性表现的分化型腺癌，浸洞深度临床诊断为Tla，直径为2 cm 2. ESD绝对适应症： 2.1无溃疡性发现的分化型腺癌(ULO)，浸润深度临床诊断为TA，直径 &gt; 2 cm 2.2分化型腺癌伴溃疡性发现(UL1)，浸润深度临床诊断为Tla，直径为 &lt; 3 cm</td></tr><tr><td align="center" valign="middle" >扩大适应症</td><td align="center" valign="middle" >无溃疡性发现的未分化型腺癌，浸润深度临床诊断为Tla，直径为 &lt; 2 cm</td></tr><tr><td align="center" valign="middle" >相对适应症</td><td align="center" valign="middle" >对不符合绝对或扩大适应症的肿瘤进行手术切除。对于患有严重合并症的老年人和高手术风险患者，解释残留疾病的风险(可能是淋巴结转移的形式)后征得患者的同意可行内镜切除。</td></tr></tbody></table></table-wrap><p>表2. 2018年日本胃癌治疗指南内镜切除适应症</p></sec><sec id="s9"><title>5. 早期胃癌治疗术后根除幽门螺旋杆菌和异时性胃癌</title><p>在早期胃癌的患者中可以发现同步胃癌、异时性胃癌。关于同步和异时性胃癌的诊断Moertel等人提出同步癌症的诊断间隔小于12个月，而异时性癌症的诊断间隔超过12个月 [<xref ref-type="bibr" rid="hanspub.39510-ref17">17</xref>]。日本关于异时性胃癌(MGC)定义为ESD后至少1年以上发生在与原发性胃癌不同部位的胃癌，并通过内窥镜检查或外科治疗确诊为癌症 [<xref ref-type="bibr" rid="hanspub.39510-ref18">18</xref>]。所以对于异时性胃癌的定义二者都强调了诊断时间应大于12个月。对于早期胃癌我们给予的首选治疗方法为内镜粘膜下剥离术(ESD)，并且可以达到完全治愈 [<xref ref-type="bibr" rid="hanspub.39510-ref19">19</xref>]。随着ESD的适应症在不断增加，相关的研究发现扩大适应症患者ESD预后与手术治疗术后患者相似 [<xref ref-type="bibr" rid="hanspub.39510-ref20">20</xref>] [<xref ref-type="bibr" rid="hanspub.39510-ref21">21</xref>]。同时有研究发现内镜治疗术后胃的保留，使得异时性胃癌(MGC)在ESD后的复发率高于手术治疗 [<xref ref-type="bibr" rid="hanspub.39510-ref22">22</xref>]。所以关于早期胃癌行内镜下治疗术后异时性胃癌的发生值得我们重视。那么关于影响异时性胃癌发生的影响因素，目前认为可能与粘膜萎缩和幽门螺旋杆菌感染有关，所以关于早期胃癌术后给予根除幽门螺旋杆菌是否可以降低异时性胃癌的发生率，以及是否根除幽门螺旋杆菌目前看法不一。在日本的胃癌治疗指南第五版 [<xref ref-type="bibr" rid="hanspub.39510-ref15">15</xref>] 明确指出对于eCuraA和eCuraB切除，建议检查幽门螺杆菌，如果阳性，则将其根除；但同时又表明对于内镜切除后根除幽门螺杆菌对异时性癌的发生的影响需要进一步调查。一项回顾性研究显示ESD后1年内成功根除幽门螺旋杆菌根除幽门螺旋杆菌可显著降低EGC术后MGC的发展 [<xref ref-type="bibr" rid="hanspub.39510-ref23">23</xref>]。另一项回顾性分析研究运用回顾性评分在一定程度上解决RCT存在的缺陷使得结果更接近临床，并表明根除幽门螺旋杆菌与降低MGC发病率无显著相关性，但成功根除幽门螺旋杆菌可降低EGC术后MGC的发展，而且影响显著。肖等人将异时性胃癌的发病率根据幽门螺旋杆菌持续感染、幽门螺旋杆菌根除、幽门螺旋杆菌阴性3种状态分类进行荟萃分析显示幽门螺杆菌阴性和幽门螺杆菌持续阳性患者的复发风险没有显著差异，表明尽管没有幽门螺杆菌感染，但包括肠化生在内的严重粘膜萎缩改变的致癌作用是不容忽视 [<xref ref-type="bibr" rid="hanspub.39510-ref24">24</xref>]。但相关研究报告了在成功根除H. pylori后诊断EGC的困难，因为EGC变得扁平，正常的柱状或低级别的不典型上皮在肿瘤组织上生长，在放大内窥镜的窄带成像下显示出“胃炎样”外观 [<xref ref-type="bibr" rid="hanspub.39510-ref25">25</xref>]。所以成功根除HP后增加了内镜关于同时性胃癌、异时性胃癌的诊断困难的问题在一定程度上影响目前关于幽门螺旋根除与异时性胃癌相关实验结果。在一项对早期胃癌患者进行长达7年的内镜监测的案例研究中提出无论H pylori感染状态如何，同步多肿瘤患者发生异时性多肿瘤的风险都很高，严重萎缩和肠上皮化生的病理诊断是同步和异时性胃肿瘤的危险因素。因此，即使在成功根除幽门螺杆菌之后，对有严重粘膜萎缩或肠化生的多发性胃癌患者，也有必要进行细致、长期的内镜监测。并指出在疾病的早期阶段通过建立一个最佳的监测策略来检测多个病变是重要的，同时异时性癌症风险的增加并没有持续超过10年的监测，为了发现在最初的内窥镜检查中可能遗漏的同步癌症，建议ESD术后进行内镜随访，包括内镜治疗术后病灶、放大内镜下微血管以及幽门螺旋杆菌感染等，每3个月、6个月、1年随访一次，术后5~10年每年回访一次 [<xref ref-type="bibr" rid="hanspub.39510-ref26">26</xref>]。</p></sec><sec id="s10"><title>6. 小结</title><p>早期胃癌内镜治疗术后根除幽门螺旋杆菌在一定程度上可以预防异时性胃癌，而且在ESD后根除幽门螺杆是日本目前保险覆盖的标准。但根除幽门螺旋杆菌能否降低异时性胃癌的发病率，以及在粘膜萎缩存在下根除幽门螺旋杆菌对异时性胃癌的影响及作用需要进一步的研究。同时在根除幽门螺旋杆菌治疗后胃粘膜发生了改变，在一定程度上增加了内镜下诊断难度，所以为了避免漏诊，建立有效的监测机制至关重要，同时增大随访年限对成功根除幽门螺旋杆菌后异时性胃癌是必要的。</p></sec><sec id="s11"><title>文章引用</title><p>刘子玥,马东瑞,刘贵生. 早期胃癌行内镜下治疗术后根除幽门螺旋杆菌的研究进展Research Progress on Eradication of Helicobacter pylori after Endoscopic Treatment for Early Gastric Cancer[J]. 临床医学进展, 2020, 10(12): 3240-3245. https://doi.org/10.12677/ACM.2020.1012485</p></sec><sec id="s12"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.39510-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Ferlay, J., Soerjomataram, I., Dikshit, et al. (2015) Cancer Incidence and Mortality Worldwide: Sources, Methods and Major Patterns in GLOBOCAN 2012. International Journal of Cancer, 136, E359-E386.  
&lt;br&gt;https://doi.org/10.1002/ijc.29210</mixed-citation></ref><ref id="hanspub.39510-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Digklia, A. and Wagner, A.D. (2016) Advanced Gastric Cancer: Current Treatment Landscape and Future Perspectives. World Journal of Gastroenterology, 22, 2403-2414. &lt;br&gt;https://doi.org/10.3748/wjg.v22.i8.2403</mixed-citation></ref><ref id="hanspub.39510-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Global Burden of Disease Cancer Collaboration, Fitzmaurice, C., Abate, D., et al. (2019) Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived with Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncology, 5, 1749-1768.</mixed-citation></ref><ref id="hanspub.39510-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., et al. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424. &lt;br&gt;https://doi.org/10.3322/caac.21492</mixed-citation></ref><ref id="hanspub.39510-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">杨之洵, 郑荣寿, 张思维, 等. 中国胃癌发病趋势及预测[J]. 中国肿瘤, 2019, 28(5): 321-326.</mixed-citation></ref><ref id="hanspub.39510-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">World Health Organization International Agency for Research on Cancer (1994) IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Volume 61 Schistosomes, Liver Flukes and Helicobacter pylori.  
&lt;br&gt;https://www.ncbi.nlm.nih.gov/books/NBK487782/</mixed-citation></ref><ref id="hanspub.39510-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Mizuguchi, A., Takai, A., Shimizu, et al. (2018) Genetic Features of Multicentric/Multifocal Intramucosal Gastric Carcinoma. International Journal of Cancer, 143, 1923-1934. &lt;br&gt;https://doi.org/10.1002/ijc.31578</mixed-citation></ref><ref id="hanspub.39510-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Kato, M., Asaka, M., Ono, S., et al. (2007) Eradication of Helicobacter pylori for Primary Gastric Cancer and Secondary Gastric Cancer after Endoscopic Mucosal Resection. Journal of Gastroenterology, 42, 16-20.  
&lt;br&gt;https://doi.org/10.1007/s00535-006-1928-5</mixed-citation></ref><ref id="hanspub.39510-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Hooi, J.K.Y., Lai, W.Y., Ng, W.K., Suen, M.M.Y., Underwood, F.E., Tanyingoh, D., et al. (2017) Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. Gastroenterology, 153, 420-429.  
&lt;br&gt;https://doi.org/10.1053/j.gastro.2017.04.022</mixed-citation></ref><ref id="hanspub.39510-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Rey, J.F. and Lambert, R. (2001) Esge Recommendations for Quality Control in Gastrointestinal Endoscopy: Guidelines for Image Documentation in Upper and Lower GI Endoscopy. Endoscopy, 33, 901-903.  
&lt;br&gt;https://doi.org/10.1055/s-2001-42537</mixed-citation></ref><ref id="hanspub.39510-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Takashi, S., Asako, T., Gen, et al. (2016) Effectiveness of Magnifying Narrow-Band Imaging Endoscopy for Differential Diagnosis between the High-Risk Mixed-Type and Low-Risk Simple-Type of Low-Grade, Well-Differentiated Gastric Tubular Adenocarcinoma. Gastroenterology Research and Practice, 2016, Article ID: 3028456.  
&lt;br&gt;https://doi.org/10.1155/2016/3028456</mixed-citation></ref><ref id="hanspub.39510-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Yagi, K., Nakamura, A., Sekine, A. and Umezu, H. (2008) Magnifying Endoscopy with Narrow Band Imaging for Early Differentiated Gastric Adenocarcinoma. Digestive Endoscopy, 20, 115-122.  
&lt;br&gt;https://doi.org/10.1111/j.1443-1661.2008.00788.x</mixed-citation></ref><ref id="hanspub.39510-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Nakayoshi, T. (2004) Magnifying Endoscopy Combined with Narrow Band Imaging System for Early Gastric Cancer Correlation of Vascular Pattern with Histopathology. Endoscopy, 36, 1080-1084.  
&lt;br&gt;https://doi.org/10.1055/s-2004-825961</mixed-citation></ref><ref id="hanspub.39510-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Japanese Gastric Cancer Association (2017) Japanese Gastric Cancer Treatment Guidelines 2014 (ver. 4). Gastric Cancer, 20, 1-19. &lt;br&gt;https://doi.org/10.1007/s10120-016-0622-4</mixed-citation></ref><ref id="hanspub.39510-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Association, J.G.C. (2020) Japanese Gastric Cancer Treatment Guidelines 2018 (5th Edition). Gastric Cancer, 1-21.</mixed-citation></ref><ref id="hanspub.39510-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Lian, J., Chen, S., Zhang, Y. and Qiu, F. (2012) A Meta-Analysis of Endoscopic Submucosal Dissection and EMR for Early Gastric Cancer. Gastrointestinal Endoscopy, 76, 763-770. &lt;br&gt;https://doi.org/10.1016/j.gie.2012.06.014</mixed-citation></ref><ref id="hanspub.39510-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Moertel, C.G., Bargen, J.A. and Soule, E.H. (1957) Multiple Gastric Cancers; Review of the Literature and Study of 42 Cases. Gastroenterology, 32, 1095-1103. &lt;br&gt;https://doi.org/10.1016/S0016-5085(57)80113-9</mixed-citation></ref><ref id="hanspub.39510-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Association, J.G.C. (2011) Japanese Classification of Gastric Carcinoma: 3rd English Edition. Gastric Cancer, 14, 101-112. &lt;br&gt;https://doi.org/10.1007/s10120-011-0041-5</mixed-citation></ref><ref id="hanspub.39510-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Gotoda, T. (2007) Endoscopic Resection of Early Gastric Cancer. Gastric Cancer, 10, 1-11.  
&lt;br&gt;https://doi.org/10.1007/s10120-006-0408-1</mixed-citation></ref><ref id="hanspub.39510-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Hasuike, N., Ono, H., Boku, N., Mizusawa, J., Takizawa, K., Fukuda, H., Oda, I., Doyama, H., Kaneko, K., Hori, S., Iishi, H., Kurokawa, Y., Muto, M. and Gastrointestinal Endoscopy Group of Japan Clinical Oncology Group (JCOG-GIESG) (2018) A Non-Randomized Confirmatory Trial of an Expanded Indication for Endoscopic Submucosal Dissection for Intestinal-Type Gastric Cancer (cT1a): The Japan Clinical Oncology Group Study (JCOG0607). Gastric Cancer, 21, 114-123. &lt;br&gt;https://doi.org/10.1007/s10120-017-0704-y</mixed-citation></ref><ref id="hanspub.39510-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Fukunaga, S., Nagami, Y., Shiba, M., Ominami, et al. (2017) Long-Term Prognosis of Expanded-Indication Differentiated-Type Early Gastric Cancer Treated with Endoscopic Submucosal Dissection or Surgery Using Propensity Score Analysis. Gastrointestinal Endoscopy, 85, 143-152. &lt;br&gt;https://doi.org/10.1016/j.gie.2016.06.049</mixed-citation></ref><ref id="hanspub.39510-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Pyo, J.H., Lee, H., Min, B.H., Lee, J.H., Choi, et al. (2016) Long-Term Outcome of Endoscopic Resection vs. Surgery for Early Gastric Cancer: A Non-Inferiority-Matched Cohort Study. The American Journal of Gastroenterology, 111, 240-249. &lt;br&gt;https://doi.org/10.1038/ajg.2015.427</mixed-citation></ref><ref id="hanspub.39510-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Nakata, R., Nagami, Y., Hashimoto, A., Sakai, T., Ominami, et al. (2019) Successful Eradication of Helicobacter pylori Could Prevent Metachronous Gastric Cancer: A Propensity Matching Analysis. Digestion, 1-10.  
&lt;br&gt;https://doi.org/10.1159/000504132</mixed-citation></ref><ref id="hanspub.39510-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Xiao, S., Li, S., Zhou, L., Jiang, W. and Liu, J. (2019) Helicobacter pylori Status and Risks of Metachronous Recurrence after Endoscopic Resection of Early Gastric Cancer: A Systematic Review and Meta-Analysis. Journal of Gastroenterology, 54, 226-237. &lt;br&gt;https://doi.org/10.1007/s00535-018-1513-8</mixed-citation></ref><ref id="hanspub.39510-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Saka, A., Yagi, K. and Nimura, S. (2016) Endoscopic and Histological Features of Gastric Cancers after Successful Helicobacter pylori Eradication Therapy. Gastric Cancer, 19, 524-530. &lt;br&gt;https://doi.org/10.1007/s10120-015-0479-y</mixed-citation></ref><ref id="hanspub.39510-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Pan, H., Fang, C., He, L., Li, H., et al. (2019) Risk of Multiple Early Gastric Cancers in a Patient with Precursor Lesions and Endoscopic Surveillance for 7 Years: A Case Report. Medicine, 98, e15686.  
&lt;br&gt;https://doi.org/10.1097/MD.0000000000015686</mixed-citation></ref></ref-list></back></article>